Gibson, Dunn & Crutcher LLP served as legal advisor to the Partnership and Lazard acted as financial advisor to the Partnership. On November 21, 2023, USD...
USD Partners LP and and USD Terminals Canada ULC’s Amendment of Revolving Credit Agreement
Calumet Specialty Products Partners, L.P.’s Corporate Transition
Gibson, Dunn & Crutcher LLP is advising Calumet Specialty Products Partners, L.P. on the transaction. Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) announced the execution of an...
Calumet Specialty Products Partners’ $325 Million Private Placement
Gibson, Dunn & Crutcher LLP is advising Calumet Specialty Products Partners, L.P. on its offering. Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) (the “Partnership” or “Calumet”) and...
Magenta Therapeutics’ Merger with Dianthus Therapeutics
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
Valaris Limited’s Senior Secured Second Lien Notes and Revolving Credit Facility
Gibson, Dunn & Crutcher LLP acted for Valaris Limited on the offering and the revolving credit facility. Valaris Limited (NYSE: VAL) and its wholly-owned subsidiary, Valaris Finance...